Regenerative Medical Technology Group files draft information statement for SEC review

• Regenerative Medical Technology Group’s shareholders authorized an increase in common shares authorized to 400 million from 100 million.
• Board action dated Aug. 17, 2026, targeted headroom for conversions tied to outstanding convertible securities and warrants totaling about 184,156,824 shares.
• Record-date capital structure: 13,138,968 common shares outstanding; 1,050,000 Series AA preferred; 1 Series CC preferred; 9,870 Series DD preferred.
• Series AA preferred carried 67% of total voting power as of Aug. 17, 2026; majority holders listed as Benito Novas, Dave Christensen.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Regenerative Medical Technology Group Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-090892), on August 18, 2026, and is solely responsible for the information contained therein.